Ketamine Hydrochloride

Nationally ranked PR+Mkt+Creative firm to support earned media strategy for leading behavioral healthcare provider ATLANTA, June 15, 2026 /PRNewswire/ -- Trevelino/Keller, a nationally ranked Integrated PR+Mkt+Creative agency, announces its client relationship with Serenity Mental Health Centers, a behavioral health provider specializing in evidence-based treatment for depression, anxiety, PTSD and other mental disorders. With more than 35 locations across the United States, Serenity Mental Health Centers is committed to expanding access to innovative and personalized mental healthcare. Its multidisciplinary team of psychiatrists, nurse practitioners and mental health specialists combines traditional psychiatric care with advanced therapies, including Transcranial Magnetic Stimulation (TMS) and ketamine infusion treatment, helping patients achieve meaningful and lasting outcomes. As demand for mental health services continues to rise nationwide, Serenity remains focused on removing barriers to care while advancing awareness of effective treatment options that support long-term wellness and recovery. The need is significant: more than one in five U.S. adults experiences a mental illness each year, yet fewer than half receive treatment, according to the Substance Abuse and Mental Health Services Administration. Compounding the challenge, the Health Resources and Services Administration reports that more than 120 million Americans live in areas with a shortage of mental health professionals, with cost and difficulty finding an available provider consistently cited as the top barriers to care. "At Serenity, our mission is to provide patients with hope through compassionate, evidence-based care and innovative treatment approaches," said George Fischer, Chief Marketing Officer, Serenity Mental Health Centers. "Today, the search for care increasingly begins online and, more and more, with AI. We selected Trevelino/Keller because credible earned media now shapes both public trust and how AI platforms surface providers. Investing in strategic public relations ensures that patients seeking evidence-based care can find Serenity wherever that search begins." Trevelino/Keller's scope of work includes earned media relations strategy and execution and thought leadership, designed to elevate Serenity's national profile within the behavioral health community and increase awareness of innovative treatment approaches available to individuals seeking mental healthcare solutions. Through targeted storytelling and strategic media engagement, the agency will support Serenity's efforts to educate patients, caregivers and healthcare stakeholders on evolving mental health treatment options. The partnership also reflects a fundamental shift in how patients find mental healthcare. Nearly half of consumers now use AI tools such as ChatGPT and Google's AI Overviews to research healthcare providers, and reliance on AI to choose a provider has more than doubled in the past year, according to rater8's 2026 Patient Choice Report. Because AI platforms draw heavily on credible third-party media coverage, earned media has become a cornerstone of answer engine optimization (AEO), directly influencing whether a provider appears in the answer when patients ask where to turn for care. "The mental health landscape continues to evolve as more individuals seek access to effective, evidence-based care," said Genna Keller, co-CEO of Trevelino/Keller. "Serenity has built a differentiated model that combines clinical expertise with innovative therapies and a patient-centered approach. We are excited to help amplify the organization's story and contribute to the broader conversation around mental health awareness and treatment accessibility." About Trevelino/Keller Trevelino/Keller is an Integrated PR+Mkt+Creative firm delivering award-winning brand, go-to-market and accelerated growth programming. In 2024, it acquired Marsden Marketing, a nationally recognized growth marketing firm, as part of its integrate and growth marketing expansion which features HubSpot Platinum Partner Status. Its vertical market B2B depth is acknowledged by its national ranking in 12 industry segments led by technology, healthcare, financial services, transportation, manufacturing, energy and franchising. Recognized as one of the 29 best firms to work for in North America, it continues to own the country's #1 talent retention. For more information, . About Serenity Mental Health Centers Serenity Mental Health Centers is a leading provider of comprehensive mental health services, dedicated to transforming the lives of patients through compassionate, innovative, and evidence-based care. With 35 locations across the country, Serenity offers a wide range of treatments tailored to address various mental health conditions, including depression, anxiety, OCD, and PTSD. Our highly skilled team of psychiatrists, nurse practitioners and mental health specialists combine innovative therapies like Transcranial Magnetic Stimulation (TMS) and ketamine infusion with personalized care to help patients achieve lasting wellness. Serenity is committed to expanding access to quality mental health care and fostering hope and recovery for individuals and families in the communities we serve. For more information, go to serenitymentalhealthcenters.com. MEDIA CONTACT Lauren Shankman [email protected] SOURCE Trevelino/Keller 21% more press release views with Request a Demo

Germany-based HMNC Brain Health (HMNC Holding GmbH) has announced a USD 50 million first closing of its Series B financing round, paired with a strategic licensing agreement granting MEDICE – The Health Family exclusive European commercialization rights for its oral ketamine candidate Ketabon (KET01). The dual transaction positions the clinical-stage neuroscience company to advance both of its lead depression programs toward Phase III readiness. MEDICE, a family-run pharmaceutical company with an established commercial presence in mental health and a market-leading position in ADHD across several European countries, led the round as the main investor. Existing investor The Maschmeyer Group also participated. Financial terms of the licensing agreement include tiered double-digit royalties on net sales and success-based commercial milestone payments, though specific figures were not disclosed. The company said proceeds will fund late-stage clinical development activities for both Ketabon (KET01) and nelivabon (BH-200), including Phase III readiness work for each program. No prior funding round details were disclosed in the announcement, and the total target size of the Series B has not been specified. Ketabon is an oral prolonged-release ketamine formulation developed as a scalable alternative to existing intravenous and intranasal ketamine-based therapies for treatment-resistant depression (TRD). The compound is being developed through a joint venture between HMNC and Develco Pharma. Ketabon is an oral prolonged-release ketamine formulation intended as an at-home alternative to Johnson & Johnson’s Spravato (esketamine), which requires supervised administration. The program has reported Phase II antidepressant activity and is being advanced toward late-stage development. Nelivabon (BH-200) is a first-in-class oral vasopressin V1b receptor antagonist being developed as a biomarker-guided precision therapy for biologically defined depressive disorders. The compound targets hypothalamic-pituitary-adrenal (HPA) axis dysfunction, a stress-response pathway implicated in a subset of patients with major depressive disorder (MDD). HMNC is co-developing a proprietary genetic companion diagnostic designed to identify patients with stress-axis biology most likely to respond to the drug. Earlier this year, the company presented positive Phase IIb data from the OLIVE trial at the American College of Neuropsychopharmacology Annual Meeting, with larger effects observed in the genetically defined responder subgroup targeted by the companion diagnostic strategy. The treatment-resistant depression space has grown more competitive following the 2019 US FDA approval of esketamine (Spravato) by Johnson & Johnson. KET01’s differentiation rests on its oral, at-home format, which contrasts with the supervised clinic-based administration required for Spravato. In the precision psychiatry space, the vasopressin V1b receptor remains a relatively unexplored target; no approved therapies currently act through this mechanism in depression, giving nelivabon first-in-class potential in a biomarker-defined patient population. The licensing agreement gives HMNC access to an established European mental health commercialization platform while preserving economics through milestone payments and royalties. MEDICE operates across multiple European countries with a particular focus on neuropsychiatry, and the company’s managing partner, Dr. med. Katja Pütter-Ammer, cited the biomarker-guided approach behind nelivabon as indicative of where the broader field is heading. For HMNC, the partnership reduces the capital and operational burden of building a European commercial organization independently, while providing milestone-linked economics tied to KET01’s development and sales trajectory. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/ Your email address will not be published. Required fields are marked * Comment * Name * Email * Website Privacy Terms About Us Copyright © 2026. AllSci Corp. All rights reserved.